(+/-)-3-ALLYL-7-HALO-8-HYDROXY-1-PHENYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES AS SELECTIVE HIGH-AFFINITY D1 DOPAMINE RECEPTOR ANTAGONISTS - SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP

被引:15
作者
BAINDUR, N
TRAN, M
NIZNIK, HB
GUAN, HC
SEEMAN, P
NEUMEYER, JL
机构
[1] NORTHEASTERN UNIV,COLL PHARM & ALLIED HLTH PROFESS,MED CHEM SECT,BOSTON,MA 02115
[2] RES BIOCHEM INC,1 STRATHMORE RD,NATICK,MA 01760
[3] UNIV TORONTO,DEPT PSYCHIAT,TORONTO M5S 1A8,ONTARIO,CANADA
[4] UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A8,ONTARIO,CANADA
关键词
D O I
10.1021/jm00079a008
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Substituted 1-phenyl-3-benzazepines form a class of compounds possessing potent and selective affinity for the D1 DA receptor. 7,8-Dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF 38393) and its 6-halo analogues are potent and selective D1 receptor agonists. Recently, the 3-allyl derivatives of SKF 38393 and its analogues were described as selective D1 agonists with higher D1 efficacy and CNS potency. In order to extend these results to compounds in the 7-halo-8-hydroxy-substituted antagonist series, we have synthesized and pharmacologically characterized 3-allyl analogues of 7-substituted (Cl, Br, H) 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines. These 3-allyl derivatives were compared with their 3-methyl and 3-unsubstituted analogues in terms of their D1 receptor affinity and selectivity. The results have been used to generate structure-affinity relationships. The D1 receptor affinity, for 3-substitution, is found to be in the order: methyl > allyl > H. For 7-substitution, the affinity is in the order: Cl = Br > H. The 3-allyl compounds show affinity close to that of the parent (3-methyl) compounds while exhibiting a slightly diminished D1 selectivity. However, the greater lipophilicity of the 3-allyl compounds may enable them to cross the blood-brain barrier more readily and thereby exhibit higher in vivo CNS potency. Thus 3-allylbenzazepines have potential as high affinity selective Dl antagonists.
引用
收藏
页码:67 / 72
页数:6
相关论文
共 27 条
[1]   DOPAMINE RECEPTOR SUBTYPES - BEYOND THE D1/D2 CLASSIFICATION [J].
ANDERSEN, PH ;
GINGRICH, JA ;
BATES, MD ;
DEARRY, A ;
FALARDEAU, P ;
SENOGLES, SE ;
CARON, MG .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (06) :231-236
[2]   INACTIVATION OF DOPAMINE D-1 OR D-2 RECEPTORS DIFFERENTIALLY INHIBITS STEREOTYPIES INDUCED BY DOPAMINE AGONISTS IN RATS [J].
ARNT, J ;
HYTTEL, J ;
MEIER, E .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 155 (1-2) :37-47
[3]   SYNTHESIS AND RECEPTOR AFFINITIES OF SOME CONFORMATIONALLY RESTRICTED ANALOGS OF THE DOPAMINE D1 SELECTIVE LIGAND (5R)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL [J].
BERGER, JG ;
CHANG, WK ;
CLADER, JW ;
HOU, D ;
CHIPKIN, RE ;
MCPHAIL, AT .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (08) :1913-1921
[4]   CHARACTERIZATION OF THE BINDING OF H-3-SCH 23390, A SELECTIVE D-1 RECEPTOR ANTAGONIST LIGAND, IN RAT STRIATUM [J].
BILLARD, W ;
RUPERTO, V ;
CROSBY, G ;
IORIO, LC ;
BARNETT, A .
LIFE SCIENCES, 1984, 35 (18) :1885-1893
[5]   SYNTHESIS AND PHARMACOLOGICAL CHARACTERIZATION OF 1-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINE, 4-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINE, AND 1-BENZYL-1,2,3,4-TETRAHYDROISOQUINOLINE AS DOPAMINE RECEPTOR LIGANDS [J].
CHARIFSON, PS ;
WYRICK, SD ;
HOFFMAN, AJ ;
SIMMONS, RMA ;
BOWEN, JP ;
MCDOUGALD, DL ;
MAILMAN, RB .
JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (10) :1941-1946
[6]  
CHIPKIN RE, 1988, J PHARMACOL EXP THER, V247, P1093
[7]  
Gold E. H., 1981, U. S. Patent, Patent No. 4284555
[8]  
HORNYKIEWICZ O, 1971, BIOGENIC AMINES PHYS, P173
[9]   SCH-23390 - THE 1ST SELECTIVE DOPAMINE D-1 ANTAGONIST [J].
HYTTEL, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1983, 91 (01) :153-154
[10]  
IORIO LC, 1983, J PHARMACOL EXP THER, V226, P462